메뉴 건너뛰기




Volumn , Issue , 2013, Pages 7-19

mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84956985322     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.122.266     Document Type: Chapter
Times cited : (4)

References (27)
  • 1
    • 79958281016 scopus 로고    scopus 로고
    • Novel antibodies against follicular non-Hodgkin's lymphoma
    • van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin's lymphoma. Best Pract. Res. Clin. Haematol. 24(2), 231-256 (2011).
    • (2011) Best Pract. Res. Clin. Haematol. , vol.24 , Issue.2 , pp. 231-256
    • van Meerten, T.1    Hagenbeek, A.2
  • 4
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    • McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
    • (1998) J. Clin. Oncol. , vol.16 , Issue.8 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-López, A.J.2    Link, B.K.3
  • 5
    • 28544435078 scopus 로고    scopus 로고
    • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005).
    • (2005) Blood , vol.106 , Issue.12 , pp. 3725-3732
    • Hiddemann, W.1    Kneba, M.2    Dreyling, M.3
  • 6
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7(5), 379-391 (2006).
    • (2006) Lancet Oncol. , vol.7 , Issue.5 , pp. 379-391
    • Pfreundschuh, M.1    Trümper, L.2    Osterborg, A.3
  • 7
    • 20144376591 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
    • Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23(9), 1984-1992 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , Issue.9 , pp. 1984-1992
    • Lenz, G.1    Dreyling, M.2    Hoster, E.3
  • 9
    • 80051722000 scopus 로고    scopus 로고
    • Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders
    • Derby L, Czuczman MS. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncol. 7(8), 963-979 (2011).
    • (2011) Future Oncol. , vol.7 , Issue.8 , pp. 963-979
    • Derby, L.1    Czuczman, M.S.2
  • 10
    • 84902819796 scopus 로고    scopus 로고
    • Advances and application of radioimmunotherapy in non-Hodgkin lymphoma
    • Stevens PL, Oluwole O, Reddy N. Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am. J. Blood Res. 2(2), 86-97 (2012).
    • (2012) Am. J. Blood Res. , vol.2 , Issue.2 , pp. 86-97
    • Stevens, P.L.1    Oluwole, O.2    Reddy, N.3
  • 11
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
    • (2008) Science , vol.321 , Issue.5891 , pp. 974-977
    • Bargou, R.1    Leo, E.2    Zugmaier, G.3
  • 12
    • 84864544136 scopus 로고    scopus 로고
    • Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma
    • Younes A, Kim S, Romaguera J et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma. J. Clin. Oncol. 30(22), 2776-2782 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , Issue.22 , pp. 2776-2782
    • Younes, A.1    Kim, S.2    Romaguera, J.3
  • 13
    • 34249664979 scopus 로고    scopus 로고
    • Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
    • Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26(25), 3704-3713 (2007).
    • (2007) Oncogene , vol.26 , Issue.25 , pp. 3704-3713
    • Leonard, J.P.1    Goldenberg, D.M.2
  • 14
    • 33748471355 scopus 로고    scopus 로고
    • Multicenter Phase II trial of immunotherapy with the humanized antiCD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
    • Strauss SJ, Morschhauser F, Rech J et al. Multicenter Phase II trial of immunotherapy with the humanized antiCD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 24(24), 3880-3886 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , Issue.24 , pp. 3880-3886
    • Strauss, S.J.1    Morschhauser, F.2    Rech, J.3
  • 15
    • 80054098574 scopus 로고    scopus 로고
    • Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    • Micallef IN, Maurer MJ, Wiseman GA et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118(15), 4053-4061 (2011).
    • (2011) Blood , vol.118 , Issue.15 , pp. 4053-4061
    • Micallef, I.N.1    Maurer, M.J.2    Wiseman, G.A.3
  • 16
    • 77957272703 scopus 로고    scopus 로고
    • High rates of durable responses with antiCD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma
    • Morschhauser F, Kraeber-Bodéré F, Wegener WA et al. High rates of durable responses with antiCD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol. 28(23), 3709-3716 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.23 , pp. 3709-3716
    • Morschhauser, F.1    Kraeber-Bodéré, F.2    Wegener, W.A.3
  • 17
    • 84860243682 scopus 로고    scopus 로고
    • Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/ refractory B-cell non-Hodgkin lymphoma
    • Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/ refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 103(5), 933-938 (2012).
    • (2012) Cancer Sci. , vol.103 , Issue.5 , pp. 933-938
    • Ogura, M.1    Hatake, K.2    Ando, K.3
  • 18
    • 0034092593 scopus 로고    scopus 로고
    • A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma
    • Messmann RA, Vitetta ES, Headlee D et al. A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma. Clin. Cancer Res. 6(4), 1302-1313 (2000).
    • (2000) Clin. Cancer Res. , vol.6 , Issue.4 , pp. 1302-1313
    • Messmann, R.A.1    Vitetta, E.S.2    Headlee, D.3
  • 19
    • 77958490178 scopus 로고    scopus 로고
    • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcyRllla-158 V/F polymorphism
    • Blum KA, Jung SH, Johnson JL et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcyRllla-158 V/F polymorphism. Ann. Oncol. 21(11), 2246-2254 (2010).
    • (2010) Ann. Oncol. , vol.21 , Issue.11 , pp. 2246-2254
    • Blum, K.A.1    Jung, S.H.2    Johnson, J.L.3
  • 20
    • 80054111050 scopus 로고    scopus 로고
    • CD30-targeted antibody therapy
    • Younes A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23(6), 587-593 (2011).
    • (2011) Curr. Opin. Oncol. , vol.23 , Issue.6 , pp. 587-593
    • Younes, A.1
  • 21
    • 84855465227 scopus 로고    scopus 로고
    • A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies
    • Fanale MA, Forero-Torres A, Rosenblatt JD et al. A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies. Clin. Cancer Res. 18(1), 248-255 (2012).
    • (2012) Clin. Cancer Res. , vol.18 , Issue.1 , pp. 248-255
    • Fanale, M.A.1    Forero-Torres, A.2    Rosenblatt, J.D.3
  • 22
    • 84863678237 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a Phase II study
    • Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a Phase II study. J. Clin. Oncol. 30(18), 2190-2196 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , Issue.18 , pp. 2190-2196
    • Pro, B.1    Advani, R.2    Brice, P.3
  • 23
    • 79959654218 scopus 로고    scopus 로고
    • Immunotoxins and other conjugates containing saporin-s6 for cancer therapy
    • Polito L, Bortolotti M, Pedrazzi M et al. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. Toxins (Basel) 3(6), 697-720.
    • Toxins (Basel) , vol.3 , Issue.6 , pp. 697-720
    • Polito, L.1    Bortolotti, M.2    Pedrazzi, M.3
  • 24
    • 84957013985 scopus 로고    scopus 로고
    • A Phase II clinical trial of SGN-40 (dacetuzumab) monotherapy in relapsed diffuse large B-cell lymphoma
    • San Francisco, CA, USA 6-9 December
    • Advani R, De Vos S, Ansell SM et al. A Phase II clinical trial of SGN-40 (dacetuzumab) monotherapy in relapsed diffuse large B-cell lymphoma. Presented at: American Society of Hematology 2008 Annual Meeting. San Francisco, CA, USA 6-9 December 2008 (Abstract 1000).
    • (2008) American Society of Hematology 2008 Annual Meeting.
    • Advani, R.1    De Vos, S.2    Ansell, S.M.3
  • 25
    • 84872047730 scopus 로고    scopus 로고
    • A pilot study of dacetuzumab (SGN-40, antihuCD40 mAb) in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    • Forero-Torres A, Bartlett N, Beaven A et al. A pilot study of dacetuzumab (SGN-40, antihuCD40 mAb) in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Leuk. Lymphoma 54(2), 277-283 (2013).
    • (2013) Leuk. Lymphoma , vol.54 , Issue.2 , pp. 277-283
    • Forero-Torres, A.1    Bartlett, N.2    Beaven, A.3
  • 26
    • 79955844043 scopus 로고    scopus 로고
    • Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory hodgkin or non-hodgkin lymphoma treated in a Phase Ia/II Clinical Trial (NCT00670592)
    • Orlando, FL, USA, 4-7 December
    • Freedman AS, Kuruvilla J, Assouline S et al. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory hodgkin or non-hodgkin lymphoma treated in a Phase Ia/II Clinical Trial (NCT00670592). Presented at: ASH Annual Meeting 2010. Orlando, FL, USA, 4-7 December 2010 (Abstract 284).
    • (2010) ASH Annual Meeting 2010.
    • Freedman, A.S.1    Kuruvilla, J.2    Assouline, S.3
  • 27
    • 34948824913 scopus 로고    scopus 로고
    • Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
    • Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007).
    • (2007) Blood , vol.110 , Issue.7 , pp. 2316-2323
    • Gallamini, A.1    Zaja, F.2    Patti, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.